EBNA1 inhibitors and their method of use

US12258314B2 · kind B2 · utility

Assignee

• The Wistar Institute of Anatomy and Biology · US

Inventors

• Troy E. Messick · Upper Darby, US
• Garry Robert Smith · Royersford, US
• Allen B. Reitz · Lansdale, US
• Paul Lieberman · Torrance, US
• Mark McDonnell · Lansdale, US
• Yan Zhang · Fort Washington, US
• Venkata Velvadapu · Ankeny, US

Key dates

• Filing date: Dec 22, 2021
• Grant date: Mar 25, 2025
• Expiry date: Dec 22, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2601/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.